Cargando…

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls

Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gut, Paweł, Czarnywojtek, Agata, Fischbach, Jakub, Bączyk, Maciej, Ziemnicka, Katarzyna, Wrotkowska, Elżbieta, Gryczyńska, Maria, Ruchała, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754364/
https://www.ncbi.nlm.nih.gov/pubmed/26925113
http://dx.doi.org/10.5114/aoms.2016.57577
_version_ 1782416001516699648
author Gut, Paweł
Czarnywojtek, Agata
Fischbach, Jakub
Bączyk, Maciej
Ziemnicka, Katarzyna
Wrotkowska, Elżbieta
Gryczyńska, Maria
Ruchała, Marek
author_facet Gut, Paweł
Czarnywojtek, Agata
Fischbach, Jakub
Bączyk, Maciej
Ziemnicka, Katarzyna
Wrotkowska, Elżbieta
Gryczyńska, Maria
Ruchała, Marek
author_sort Gut, Paweł
collection PubMed
description Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The awareness of potential causes influencing the false results of its concentrations simplifies diagnosis and treatment. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. The molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. We present the evaluation of chromogranin A as a marker of neuroendocrine tumors in clinical practice and the possible factors that may affect the outcome of its concentration.
format Online
Article
Text
id pubmed-4754364
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-47543642016-02-26 Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls Gut, Paweł Czarnywojtek, Agata Fischbach, Jakub Bączyk, Maciej Ziemnicka, Katarzyna Wrotkowska, Elżbieta Gryczyńska, Maria Ruchała, Marek Arch Med Sci State of the Art Paper Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The awareness of potential causes influencing the false results of its concentrations simplifies diagnosis and treatment. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. The molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. We present the evaluation of chromogranin A as a marker of neuroendocrine tumors in clinical practice and the possible factors that may affect the outcome of its concentration. Termedia Publishing House 2016-02-02 2016-02-01 /pmc/articles/PMC4754364/ /pubmed/26925113 http://dx.doi.org/10.5114/aoms.2016.57577 Text en Copyright © 2016 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle State of the Art Paper
Gut, Paweł
Czarnywojtek, Agata
Fischbach, Jakub
Bączyk, Maciej
Ziemnicka, Katarzyna
Wrotkowska, Elżbieta
Gryczyńska, Maria
Ruchała, Marek
Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
title Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
title_full Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
title_fullStr Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
title_full_unstemmed Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
title_short Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
title_sort chromogranin a – unspecific neuroendocrine marker. clinical utility and potential diagnostic pitfalls
topic State of the Art Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754364/
https://www.ncbi.nlm.nih.gov/pubmed/26925113
http://dx.doi.org/10.5114/aoms.2016.57577
work_keys_str_mv AT gutpaweł chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls
AT czarnywojtekagata chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls
AT fischbachjakub chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls
AT baczykmaciej chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls
AT ziemnickakatarzyna chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls
AT wrotkowskaelzbieta chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls
AT gryczynskamaria chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls
AT ruchałamarek chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls